Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)

NCT07716865 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
Hemorrhage Brain
Hemorrhage Cerebral

Interventions

DRUG: NACA

Sponsor

Arctic Therapeutics